News Headlines

  1. Catalent Extends Global Commercial Spray Drying Capabilities In Europe

    Catalent, Inc., the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, recently announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, U.K. facility.

  2. Onyx Scientific Makes Strategic Investment In Commercial API License

    Onyx Scientific has announced that it has made a strategic investment to position the company for a commercial API license. Driven by growing demand for flexible, specialist and small-scale API manufacture, the investment will see Onyx expand its UK facility, putting in place the infrastructure to take customers’ projects from concept right the way through to commercialisation.

  3. Pharmaceutics International, Inc. (Pii) Announces The Expansion Of Its Commercial Team

    Pharmaceutics International, Inc. (Pii), a Contract Development and Manufacturing Organization (CDMO) headquartered in Hunt Valley, Maryland, is pleased to announce the expansion of its commercial team with the additions of Wayne Ideus, Wayne Grellner and Ryan McFarlane.

  4. Lonza To Acquire Sterile Fill And Finish Facility From Novartis

    Lonza recently announced its entry into a binding contractual commitment for the purchase of a sterile drug product fill & finish facility from Novartis.

  5. FLAMMA Acquires Teva’s Philadelphia cGMP Facility Marking Entry Into The US Marketplace With Labs & Pilot Plant

    Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that the company has acquired the Teva’s Chemical Synthesis Center in Malvern, PA in the Philadelphia area.

  6. Scott Gottlieb Elected To Pfizer’s Board Of Directors

    Pfizer Inc. recently announced the election of Dr. Scott Gottlieb to its Board of Directors, effective immediately. Dr. Gottlieb, age 47, was also appointed to the Regulatory and Compliance Committee and the Science and Technology Committee of Pfizer’s Board.

  7. Rafael Pharmaceuticals Enters Into Out-Licensing Agreement With Ono Pharmaceutical To Accelerate Clinical Development And Commercialization Of Cancer Drug Candidate CPI-613® (Devimistat) In Japan And Other Asian Countries

    Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has entered into an out-licensing agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), a pharmaceutical company committed to creating innovative medicines

  8. AbbVie To Acquire Allergan In Transformative Move For Both Companies

    AbbVie Inc. (NYSE: ABBV) and Allergan plc (NYSE: AGN) announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019.

  9. Ropack Adds Contract Packaging Capacity With New Blister Packaging, Serialization And Cartoner Line

    Ropack Pharma Solutions is proud to introduce their newest blister packaging line (Uhlmann BEC 300) that can help with serialization, packaging and cartoning solutions.

  10. Piramal Pharma Solutions Invests $10 Million USD To Expand Its High Potency API Capability In Its Riverview Facility In U.S.

    Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO), today announced the Grand Opening of a new wing at the Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs).